For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
18
views
46
references
 Top references
cited by
51
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      584
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis

      systematic-review

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Conventional measures to evaluate COPD may fail to capture systemic problems, particularly musculoskeletal weakness and cardiovascular disease. Identifying these manifestations and assessing their association with clinical outcomes (ie, mortality, exacerbation and COPD hospital admission) is of increasing clinical importance.

          Objective

          To assess associations between 6 min walk distance (6MWD), heart rate, fibrinogen, C reactive protein (CRP), white cell count (WCC), interleukins 6 and 8 (IL-6 and IL-8), tumour necrosis factor-alpha, quadriceps maximum voluntary contraction, sniff nasal inspiratory pressure, short physical performance battery, pulse wave velocity, carotid intima-media thickness and augmentation index and clinical outcomes in patients with stable COPD.

          Methods

          We systematically searched electronic databases (August 2018) and identified 61 studies, which were synthesised, including meta-analyses to estimate pooled HRs, following Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

          Results

          Shorter 6MWD and elevated heart rate, fibrinogen, CRP and WCC were associated with higher risk of mortality. Pooled HRs were 0.80 (95% CI 0.73 to 0.89) per 50 m longer 6MWD, 1.10 (95% CI 1.02 to 1.18) per 10 bpm higher heart rate, 3.13 (95% CI 2.14 to 4.57) per twofold increase in fibrinogen, 1.17 (95% CI 1.06 to 1.28) per twofold increase in CRP and 2.07 (95% CI 1.29 to 3.31) per twofold increase in WCC. Shorter 6MWD and elevated fibrinogen and CRP were associated with exacerbation, and shorter 6MWD, higher heart rate, CRP and IL-6 were associated with hospitalisation. Few studies examined associations with musculoskeletal measures.

          Conclusion

          Findings suggest 6MWD, heart rate, CRP, fibrinogen and WCC are associated with clinical outcomes in patients with stable COPD. Use of musculoskeletal measures to assess outcomes in patients with COPD requires further investigation.

          Trial registration number

          CRD42016052075.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Susceptibility to exacerbation in chronic obstructive pulmonary disease.

          John R. Hurst, Jørgen Vestbo, Antonio Anzueto … (2010)
          Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.)
          Article 0 comments Cited 1024 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

            B.R. Celli, W MacNee, A Agusti … (2004)
            Article 0 comments Cited 467 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD.

              Ciro Casanova, Armando Jaime, Alexander P. N. A. de Porto … (2008)
              The distance walked in the 6-min walk test (6MWT) predicts mortality in patients with severe COPD. Little is known about its prognostic value in patients with a wider range of COPD severity, living in different countries, and the potential additional impact of oxygen desaturation measured during the test. We enrolled 576 stable COPD outpatients in Spain and the United States and observed them for at least 3 years (median, 60 months). We measured FEV1, body mass index, Pao2, Charlson comorbidity score, 6-min walk distance (6MWD), and oxygen saturation by pulse oximetry (Spo2) during the 6MWT. Desaturation was defined as a fall in Spo2 > or = 4% or Spo2 < 90%. Regression analysis helped determine the association between these variables and all-cause and respiratory mortality. The 6MWD was a good predictor of all-cause and respiratory mortality primarily in patients with FEV1 < 50% of predicted (p < 0.001) after adjusting for all covariates. Patients with desaturation during the 6MWT had a higher mortality rate than patients without desaturation (67% vs 38%, p < 0.001). Oxygen desaturation predicted mortality (relative risk, 2.63; 95% confidence interval, 1.53 to 4.51; p < 0.001) but with less power than Pao2 at rest. The 6MWD helps predict mortality primarily in patients with severe COPD. Although the oxygen desaturation profile during the 6MWT improves the predictive ability of the 6MWD, it appears to be of less relevance than in other lung diseases and than the resting Pao2.
              Article 0 comments Cited 90 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Thorax
                Journal ID (iso-abbrev): Thorax
                Journal ID (hwp): thoraxjnl
                Journal ID (publisher-id): thorax
                Title: Thorax
                Publisher: BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                ISSN (Print): 0040-6376
                ISSN (Electronic): 1468-3296
                Publication date (Print): May 2019
                Publication date (Electronic): 7 January 2019
                Volume: 74
                Issue: 5
                Pages: 439-446
                Affiliations
                [1 ] departmentDepartment of Medicine, Experimental Medicine and Immunotherapeutics , University of Cambridge , Cambridge, UK
                [2 ] departmentCardiovascular Epidemiology Unit, Department of Public Health and Primary Care , University of Cambridge , Cambridge, UK
                [3 ] departmentDepartment of Cardiology , Copenhagen University Hospital Rigshospitalet , Copenhagen, Denmark
                [4 ] departmentCopenhagen City Heart Study , Frederiksberg Hospital , Copenhagen, Denmark
                [5 ] departmentDivision of Pulmonology, Department of Internal Medicine , Botucatu Medical School, Univ Estadual Paulista, UNESP , Botucatu, Brazil
                [6 ] departmentDepartment of Physiotherapy , Federal University of Sao Carlos (UFSCar) , São Carlos/São Paulo, Brazil
                [7 ] departmentInternal Medicine and Emergency Medicine, Kantonsspital Aarau , Univertsity of Basel , Aarau, Switzerland
                [8 ] departmentLungenClinic Grosshansorf, Airway Research Center North , German Center for Lung Research , Grosshansdorf, Germany
                [9 ] Worldwide Epidemiology, GlaxoSmithKline R&D , Uxbridge, UK
                [10 ] Respiratory Muscle Laboratory, Royal Brompton Hospital , London, UK
                Author notes
                [Correspondence to ] Mr. Jilles M Fermont, Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB1 8RN, UK; jmf88@ 123456medschl.cam.ac.uk
                Author information
                http://orcid.org/0000-0002-1070-3661
                Article
                Publisher ID: thoraxjnl-2018-211855
                DOI: 10.1136/thoraxjnl-2018-211855
                PMC ID: 6484697
                PubMed ID: 30617161
                SO-VID: 3a38428c-9f58-4751-8493-b3ecf514c8ef
                Copyright © © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
                License:

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

                History
                Date received : 26 March 2018
                Date revision received : 31 October 2018
                Date accepted : 19 November 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100004330, GlaxoSmithKline;
                Categories
                Subject: Chronic Obstructive Pulmonary Disease
                Subject: 1506
                Subject: 2313
                Series title: Original article
                Custom metadata
                special-feature unlocked

                ScienceOpen disciplines: Surgery
                Keywords: copd epidemiology
                Data availability:
                ScienceOpen disciplines: Surgery
                Keywords: copd epidemiology

                Comments

                Comment on this article

                scite_

                Similar content584

                See all similar

                Cited by51

                See all cited by

                Most referenced authors1,670

                See all reference authors